Results 81 to 90 of about 724,283 (165)

ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS? [PDF]

Arquivos de Gastroenterologia
Inflammatory bowel diseases (IBD) currently impose an immense social and economic burden on society in terms of both direct and indirect healthcare costs. Their incurable and progressive nature results in an unavoidable lifetime expense. The introduction
Fabio Vieira TEIXEIRA, Laurent PEYRIN-BIROULET, Silvio DANESE   +2 more
doaj   +1 more source

Exploring How Gerontological Nursing Telephone Support Can Assist Informal Caregivers of Older Adults at Hospital Discharge—A Qualitative Study

Journal of Clinical Nursing, Volume 35, Issue 9, Page 3900-3911, September 2026.
ABSTRACT Aim and Objective To explore how receiving gerontological nurse telephone support assisted caregivers of older adults to provide care after hospital discharge. Background Informal caregivers are vital to the recovery of older patients after hospital discharge, but often feel under‐prepared and unsupported.
Cheng Yen Loo, Susan Slatyer, Ami Kamdar, Trish Starling, Keith D. Hill, Laurie Grealish, Howard Lance, Anne‐Marie Hill   +7 more
wiley   +1 more source

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

Biologics: Targets & Therapy, 2022
Valeria Dipasquale, Ugo Cucinotta, Claudio Romano Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G.
Dipasquale V, Cucinotta U, Romano C
doaj  

Clinical significance of vestibular assessment in otosclerosis [PDF]

Al-Azhar International Medical Journal
Background: Otosclerosis, a 1ry osteodystrophy of the otic capsule, causes stapes fixation, progressive hearing loss, and may involve the vestibular system.
Ahmed Almeciry, Ahmed Ismail Abbas, Ali Azab   +2 more
doaj   +1 more source

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Therapeutic Advances in Gastroenterology, 2019
Background: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the
Ágnes Milassin, Anna Fábián, Tamás Molnár   +2 more
doaj   +1 more source

Is CT-P13 As Effective As Infliximab In Controlling Pain In Adult Patients With Rheumatoid Arthritis? [PDF]

, 2020
OBJECTIVE: The objective of this selective EBM review is to determine whether or not CTP13 is as good as infliximab in controlling pain in adult patients with rheumatoid arthritis. STUDY DESIGN: A review of three double-blind randomized controlled trials
Nazareno, Emily
core   +1 more source

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Biologics: Targets & Therapy, 2018
Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI,
Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I   +6 more
doaj  

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)

Drug Design, Development and Therapy, 2020
Soohyun Kim, 1, 2,* Siun Kim, 1, 2,* Howard Lee 1– 4 1Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea; 2Center for Convergence Approaches in Drug Development,
Kim S, Kim S, Lee H
doaj  

Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico

Revista de Gastroenterología de México (English Edition), 2018
The biotechnology-derived medicines known as biosimilars are defined as non-originator treatments that have demonstrated quality, efficacy, and safety comparable to the reference biologic drug.
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez, J.K. Yamamoto-Furusho   +9 more
doaj   +1 more source

Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México

Revista de Gastroenterología de México, 2018
Resumen: Los medicamentos biotecnológicos biocomparables son definidos como tratamientos no innovadores que han demostrado calidad, eficacia y seguridad comparable al medicamento de referencia.
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez, J.K. Yamamoto-Furusho   +9 more
doaj   +1 more source